Overview

A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors

Status:
Active, not recruiting

Trial end date:
2023-03-18

Target enrollment:

Participant gender:

Summary

This study will assess the efficacy, safety and tolerability of pomalidomide in children and young adults aged 1 to < 21 years with recurrent or progressive primary brain tumors in one of four primary brain tumor types: high-grade glioma (HGG), medulloblastoma, ependymoma and diffuse intrinsic pontine glioma (DIPG).

Phase:

Phase 2

Details

Lead Sponsor:

Celgene

Treatments:

Pomalidomide
Thalidomide